NSI-189 is an oral investigational compound that promotes hippocampal neurogenesis, utilized off-label primarily for mood improvement and cognitive enhancement. Users typically run a daily dose of 40 mg, though reported intake ranges widely from 200 µg to 50 mg without a standardized cycling protocol. While users occasionally report changes in sleep patterns and dream intensity, the primary tradeoff is that the evidence base for these human applications remains thin, as the compound lacks FDA approval and most exploratory research lacks published results. Injection-site reactions, histamine responses, and gastrointestinal issues have not been a consistent theme in community reports.
Data last updated
Measured on 5 of 6 axes
Evidence shape
NSI-189 currently sits at a low evidence tier, as there are no published human studies to support its use. While four trials have been registered—including two completed studies focused on depression and major depressive disorder—the research remains confined to early-stage, exploratory phases and preclinical animal models. The absence of published results from these completed trials limits the ability to verify efficacy or safety, leaving the peptide’s clinical profile largely uncharacterized beyond its initial mechanistic research.
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Depression
2 studies · 2 completed
Major Depressive Disorder
2 studies
Treatment studies
1 study
2 completed study rows are present, but endpoint pass/fail classification is still pending.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How NSI-189 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
The two completed trials of NSI‑189 did not provide a reliably extracted dose; participants received the peptide orally each day, but the exact milligram amount per administration is not reported.
No structured protocol details captured for this tier yet.
Community reports center around 40 mg taken orally, with most sources falling in the 20–80 mg range; a smaller subset reports doses of 200–600 mcg. Dosing frequency was not consistently specified across these reports.